Table 2.
Comparison of overall survival (OS) without or with VeriStrat status—when considering specific factors associated with poor prognosis and histology, all patients had active supportive care only.
| Survival | All patients (ignoring VeriStrat) | VeriStrat Good | VeriStrat Poor | % with VeriStrat Good |
|---|---|---|---|---|
| Age ≥75 years (n = 143) | ||||
| Median OS, months | 4.3 [4.1] | 5.6 | 3.4 | 58 |
| 1-year rate (95% CI) | 19 (12–25) [17] | 29 (19–38) [26] | 5 (0–10) | |
| 2-year rate (95% CI) | 5 (1–9) [4] | 9 (3–15) [7] | 0 | |
| ECOG 2–3 (n = 177) | ||||
| Median OS, months | 3.8 | 4.4 | 3.6 | 50 |
| 1-year rate | 12 (7–17) | 17 (9–25) | 7 [1–12] | |
| 2-year rate | 4 (1–7) | 8 (2–14) [7] | 0 | |
| Stage IV (n = 140) | ||||
| Median OS, months | 3.4 [3.3] | 4.3 [4.1] | 2.8 | 54 |
| 1-year rate | 11 (6–16) [9] | 18 (9–26) [15] | 3 (0–7) | |
| 2-year rate | 4 (1–7) [2] | 7 (1–14) [4] | 0 | |
| Adenocarcinoma (n = 77) | ||||
| Median OS, months | 4.1 [3.9] | 5.6 | 3.6 | 60 |
| 1-year rate | 11 (4–18) [9] | 19 (7–30) [15] | 0 | |
| 2-year rate | 5 (1–12) [3] | 8 (1–16) [5] | 0 | |
| Squamous cell (n = 95) | ||||
| Median OS, months | 4.6 | 5.3 [6.3] | 4.2 [4.4] | 43 |
| 1-year rate | 22 (14–30) [20] | 32 (17–46) | 11 (3–19) | |
| 2-year rate | 3 (0–7) [3] | 7 (0–15) | 0 | |
ECOG, Eastern Cooperative Oncology Group; CI, confidence interval.
The aforementioned results were the same when patients with EGFR positive tumours were excluded, except where shown in square brackets.